[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alume Biosciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100566970","phase-2-a-study-of-bevonescein-in-patients-undergoing-abdominopelvic-surgery-100566970",false,"NCT06662097","A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery","Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery","Inclusion Criteria:\n\n* Must be a minimum of 18 years of age\n* Study participant is planning to proceed with surgery\n* Willing to provide informed consent\n* Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after.\n* Females of childbearing potential must have a negative pregnancy test at screening and during the study.\n\nExclusion Criteria:\n\n* Patient has had prior surgery at the intended surgical site.\n* Patient has abnormal cardiac rhythm not controlled by medication.\n* Patient has moderate to severe renal impairment.\n* Patient has a history of fluorescein allergy.\n* Patient has a history of drug-related anaphylactic.\n* Presence of a concurrent disease or condition that may interfere with study participation.\n* Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance.\n* Use of any Investigational Product or investigational medial device within 30 days prior to screening.",true,"ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery",[27,28,29],"Surgery","Nerve Injury","Imaging","RECRUITING","2024-10-25",{"date":33,"type":34},"2024-10-28","ACTUAL",{"date":36,"type":34},"2024-10-16",{"date":38,"type":21},"2025-09",{"name":40,"class":41},"Alume Biosciences, Inc.","INDUSTRY",""]